Literature DB >> 12150192

Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection.

Robert C Welliver1, Roberto P Garofalo, Pearay L Ogra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12150192     DOI： 10.1097/00006454-200205000-00033

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  23 in total

Review 1.  Pathogenesis of respiratory syncytial virus infection in the murine model.

Authors:  R Stokes Peebles; Barney S Graham
Journal:  Proc Am Thorac Soc       Date:  2005

Review 2.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

3.  CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Authors:  Tatiana Chirkova; Songbai Lin; Antonius G P Oomens; Kelsey A Gaston; Seyhan Boyoglu-Barnum; Jia Meng; Christopher C Stobart; Calvin U Cotton; Tina V Hartert; Martin L Moore; Assem G Ziady; Larry J Anderson
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

4.  Local production of inflammatory mediators during childhood parainfluenza virus infection.

Authors:  Rana E El Feghaly; Lindsay McGann; Cynthia A Bonville; Patrick J Branigan; Manika Suryadevera; Helene F Rosenberg; Joseph B Domachowske
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

Review 5.  The immune response to respiratory syncytial virus infection: friend or foe?

Authors:  Robert C Welliver
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

6.  Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Jesús Saavedra-Lozano; Mónica Fonseca Aten; Jeanine Hatfield; Payal Kapur; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Expression of CTLA-4 (CD152) in peripheral blood T cells of children with influenza virus infection including encephalopathy in comparison with respiratory syncytial virus infection.

Authors:  H Ayukawa; T Matsubara; M Kaneko; M Hasegawa; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

8.  Gene expression of nucleic acid-sensing pattern recognition receptors in children hospitalized for respiratory syncytial virus-associated acute bronchiolitis.

Authors:  Carolina Scagnolari; Fabio Midulla; Alessandra Pierangeli; Corrado Moretti; Enea Bonci; Rosaria Berardi; Daniela De Angelis; Carla Selvaggi; Paola Di Marco; Enrico Girardi; Guido Antonelli
Journal:  Clin Vaccine Immunol       Date:  2009-04-22

9.  Identification of gene biomarkers for respiratory syncytial virus infection in a bronchial epithelial cell line.

Authors:  Yuh-Chin T Huang; Zhuowei Li; Xhevahire Hyseni; Michael Schmitt; Robert B Devlin; Edward D Karoly; Joleen M Soukup
Journal:  Genomic Med       Date:  2009-05-15

10.  TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

Authors:  Teresa R Johnson; Srinivas Rao; Robert A Seder; Man Chen; Barney S Graham
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.